Jose Padin-Rosado, MD
Neurology · Albuquerque, NMNPI 1831112762
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Neuropace, Inc. at 44.4% of the total. Reporting peaked in 2023 at $154 and has fallen 75.2% since, to $38 in 2025. That places this record below the midpoint for neurology clinicians in NM, where the typical reported total is $623.
Across 18 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$188
- UCB, Inc.$104
- Banner Life Sciences, LLC$28
- Sanofi$27
- Sanofi-aventis U.S. LLC$23
- Impel Pharmaceuticals Inc.$21
- plus $32 from 2 others
What the payments were for
- Food & beverage$422100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 8 | $188 |
| UCB, Inc. | 3 | $104 |
| Banner Life Sciences, LLC | 2 | $28 |
| Sanofi | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| Livanova USA, Inc. | 1 | $19 |
| Medtronic | 1 | $12 |
How this compares
$422 in reported general payments places this provider in the 45th percentile of 91 neurology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 96 | $13,051 |
| Levetiracetam | 214 | $9,514 |
| TegretolCarbamazepine | 16 | $8,947 |
| Carbamazepine ErCarbamazepine | 40 | $3,896 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $3,812 |
| Oxcarbazepine | 86 | $3,588 |
| Lamotrigine | 151 | $2,004 |
| Zonisamide | 68 | $1,559 |
| Levetiracetam ErLevetiracetam | 14 | $640 |
| Phenytoin Sodium Extended | 35 | $577 |
| Clobazam | 12 | $498 |
| Clonazepam | 41 | $480 |
| Topiramate | 31 | $479 |
| Divalproex Sodium | 11 | $408 |
| Phenobarbital | 14 | $320 |
Paid to pharmacies, not to this prescriber.
Other neurology in Albuquerque
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Timothy OwnbeyAlbuquerque$90K
- Gerson Suarez CedenoAlbuquerque$44K
- Corey FordAlbuquerque$27K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
- Vanessa Licona SanjuanAlbuquerque$16K
- Daniel ShibuyaAlbuquerque$13K
- Alfred van BaakAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.